

REMARKS

The Examiner indicated on page 3 of the Office Action that the original application text contained a number of spelling errors. Applicants have amended the specification to correct grammatical errors and the spelling errors mentioned by the Examiner as well as others.

Claims 16, 20-25, 30-35 and 71-93 are pending in this application. Applicants acknowledge that the full scope of the pending claims has been examined as explained on page 2 of the Office Action.

The Examiner objected to claims 71 and 91 as lacking antecedent basis for reciting the administration of "another antihypertensive." Applicants believe that the claims were proper in reciting the administration of "another antihypertensive" because ramipril and ramiprilat are themselves antihypertensives. Both claims have nonetheless been amended to recite possibly administering "an antihypertensive" in addition to ramipril or ramiprilat or a pharmaceutically acceptable salt of ramipril or ramiprilat.

The Examiner rejected claims 16, 20-25, 30-35, 71 and 74-91 under 35 U.S.C. § 112, second paragraph, as being indefinite in the use of the term "derivative." The amendments to claims 16 and 77 remove that term and should render this rejection moot.

In view of these amendments and remarks, applicants respectfully request reconsideration and reexamination of this application and the timely allowance of the pending claims. Please grant any extensions of time required to enter this Amendment and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 19, 2005

By: 
Steven J. Scott
Reg. No. 43,911